Publications by authors named "ZheXuan Deng"
Article Synopsis
- Immune checkpoint inhibitor-induced immune-mediated hepatitis (ICI-IMH) can lead to an increased risk of liver failure (LF) in patients with hepatocellular carcinoma (HCC), prompting the need for effective treatments.
- A randomized controlled trial will enroll 60 participants, comparing a combination treatment using a double plasma molecular adsorption system (DPMAS) and low-volume plasma exchange (LPE) against standard plasma exchange (PE) to assess efficacy in reducing mortality and improving liver function.
- The primary focus will be on the mortality rate after 12 weeks, with secondary assessments including changes in liver disease scoring and the occurrence of adverse events.
This study aimed to evaluate how the timing of transarterial chemoembolization (TACE) relative to systemic therapy (tyrosine-kinase inhibitors [TKIs] and immune checkpoint inhibitors [ICIs]) influences oncological outcomes in patients with hepatocellular carcinoma (HCC). A retrospective analysis was conducted on HCC patients treated with TACE plus TKIs and ICIs from January 2018 to February 2023. We compared objective response rate (ORR), disease control rate (DCR), overall survival (OS), and progression-free survival (PFS) between patients receiving TACE before versus after systemic therapies.
View Article and Find Full Text PDFCurrent evidence suggests that the mortality rate of intermediate-stage hepatitis B virus (HBV)-related acute-on-chronic liver failure (ACLF) remains high. We aimed to investigate the safety and efficacy of double plasma molecular adsorption system (DPMAS) with sequential low-volume plasma exchange (LPE) treatment in intermediate-stage HBV-related ACLF. This prospective study recruited intermediate-stage HBV-related ACLF patients and was registered on ClinicalTrials.
View Article and Find Full Text PDF